This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Aldara for the Treatment of Large and/or Multiple sBCC

This study has been completed.
Information provided by:
MEDA Pharma GmbH & Co. KG Identifier:
First received: September 12, 2005
Last updated: September 24, 2008
Last verified: September 2008
BCC is the most common form of skin cancer. Current treatment is often surgery but this can be limited by the number of lesions, their location the age of the patient or the potential cosmetic outcome. The purpose of this study is to evaluate the effectiveness of imiquimod, on a non surgical treatment, in subjects with multiple of large sBCCs.

Condition Intervention Phase
Carcinoma, Basal Cell Drug: Imiquimod Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Study to Evaluate the Efficacy and Tolerance of Imiquimod 5% Cream for the Treatment of a Large and/or Multiple Superficial Basal Cell Carcinoma.

Resource links provided by NLM:

Further study details as provided by MEDA Pharma GmbH & Co. KG:

Primary Outcome Measures:
  • Clinical clearance of sBCC [ Time Frame: 12 or 16 weeks after treatment ]

Secondary Outcome Measures:
  • Reduction in size of tumour [ Time Frame: 12 or 16 weeks after treatment ]
  • Rate of clearance, Cosmetic outcome [ Time Frame: 12 or 16 weeks after treatment ]
  • Sustained clearance rate over 3 year follow-up [ Time Frame: 3 years after treatment ]
  • Tolerability & QoL [ Time Frame: 12 or 16 weeks after treatment ]

Enrollment: 111
Study Start Date: May 2003
Study Completion Date: October 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: imiqimod 5% cream Drug: Imiquimod
cream 5%, 5 days out of seven, for 6 weeks


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • One or more sBCC on torso, neck or face
  • Total surface area <= 40 sq cm

Exclusion Criteria:

  • Pregnancy or women who are breastfeeding
  • Xeroderma pigmentosum, albinism, epidermodysplasia verruciformis, any genetic anomaly accompanied by skin tumors
  • Metatypical, adnexal, or sclerodermiform carcinomas
  • Current or other previous malignant skin tumor (epidermoid carcinoma, melanoma) in the region of the current lesion
  • Known HIV positive serology
  • Skin tumor that is already or highly likely to become metastatic
  • Presence of a clinically significant anomaly or illness (immunological, cardiovascular, pulmonary, hematological, neurological, hepatic, renal, endocrine, gastrointestinal, collagenous)
  • Previous organ transplant history
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00189280

Service de DermatologieHôpital Dupuytren
Limoges, France, 87042
Sponsors and Collaborators
MEDA Pharma GmbH & Co. KG
Principal Investigator: Professeur Bedane Service de DermatologieHôpital Dupuytren, LIMOGES
  More Information

Responsible Party: Elena Rizova, MD, Medical and Scientific Affairs, Europe & MENA, Laboratoires 3M Santé Identifier: NCT00189280     History of Changes
Other Study ID Numbers: 1475-IMIQ
Study First Received: September 12, 2005
Last Updated: September 24, 2008

Keywords provided by MEDA Pharma GmbH & Co. KG:
Aldara, sBCC

Additional relevant MeSH terms:
Carcinoma, Basal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Basal Cell
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Interferon Inducers processed this record on August 18, 2017